HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Mary B Daly Selected Research

Ovariectomy (Oophorectomy)

5/2015Salpingectomy as a means to reduce ovarian cancer risk.
1/2015Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion.
11/2014Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
5/2013Understanding the needs of women considering risk-reducing salpingo-oophorectomy.
4/2012Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
11/2010Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
11/2010New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.
9/2010Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
3/2009A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.
3/2008Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Mary B Daly Research Topics

Disease

22Breast Neoplasms (Breast Cancer)
02/2016 - 05/2002
20Neoplasms (Cancer)
02/2016 - 05/2002
18Ovarian Neoplasms (Ovarian Cancer)
02/2016 - 05/2002
3Carcinoma (Carcinomatosis)
11/2015 - 05/2002
2Prostatic Neoplasms (Prostate Cancer)
11/2015 - 01/2008
2Noninfiltrating Intraductal Carcinoma (DCIS)
01/2014 - 12/2006
1Granulosa Cell Tumor
01/2015
1Disease Susceptibility (Diathesis)
01/2014
1Fanconi Anemia (Fanconi's Anemia)
01/2011
1Ductal Carcinoma
01/2007
1Cysts
12/2003

Drug/Important Bio-Agent (IBA)

8Estrogens (Estrogen)FDA Link
02/2016 - 03/2006
6HormonesIBA
02/2016 - 01/2006
4Biological Markers (Surrogate Marker)IBA
11/2015 - 10/2007
3TamoxifenFDA LinkGeneric
09/2013 - 12/2006
2DNA (Deoxyribonucleic Acid)IBA
11/2015 - 04/2014
2Proteins (Proteins, Gene)IBA
09/2011 - 01/2011
2polyglutamineIBA
03/2006 - 01/2006
1Codon (Codons)IBA
02/2016
1familial Prostate cancerIBA
11/2015
11,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
11/2015
1Hazardous Substances (Hazardous Materials)IBA
05/2015
1DNA Glycosylases (DNA Glycosylase)IBA
04/2014
1Deoxyribonuclease (Pyrimidine Dimer)IBA
04/2014
1GuanineIBA
04/2014
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
04/2014
1Formaldehyde (Formol)FDA Link
01/2014
1ParaffinIBA
01/2014
1Untranslated RNA (Noncoding RNA)IBA
01/2012
1Progesterone Receptors (Progesterone Receptor)IBA
01/2011
1Genetic Markers (Genetic Marker)IBA
09/2009
1MicroRNAs (MicroRNA)IBA
09/2009
1Insulin (Novolin)FDA Link
01/2009
1Histidine (L-Histidine)FDA Link
01/2008
1bipiperidyl mustard (BPM)IBA
12/2007
1Raloxifene (Evista)FDA Link
10/2007
1Phenobarbital (Luminal)FDA Link
01/2007
1Cyclin D1IBA
01/2007
1GonadotropinsIBA
11/2006
1Complement System Proteins (Complement)IBA
03/2006
1Glutamine (L-Glutamine)FDA Link
01/2006

Therapy/Procedure

18Ovariectomy (Oophorectomy)
05/2015 - 05/2002
6Mastectomy (Mammectomy)
11/2014 - 05/2002
2Chemoprevention
01/2004 - 01/2003
1Salpingectomy
05/2015
1Laparotomy
01/2015
1Hysterectomy
01/2015
1Individualized Medicine
01/2014
1Segmental Mastectomy (Lumpectomy)
12/2006
1Hormone Replacement Therapy (Therapy, Hormone Replacement)
11/2005